Background: Respiratory recurrent papillomatosis (RRP) is a fatal disease with no known cure. In severe RRP cases, systemic bevacizumab (SB) could be used as adjuvant therapy. Objective: This study aims to determine the extent and type of evidence in relation to the clinical outcomes of RRP after SB treatment. Methods: Participants with RRP of all genders are included in this scoping review. There were no exclusion criteria (country, language, or document type). The information sources included experimental, quasi-experimental, and analytical observational studies. Unpublished data will not be covered, but gray literature was covered. Screening, paper selection, and data extraction were all done by two independent reviewers. This procedure was performed blindly. Results: Of the 175 unique records found, 15 were eligible for inclusion. Fourteen studies were included after applying inclusion and exclusion criteria. Thirty-four patients in these studies came from the United States, India, Germany, Colombia, Argentina, Chile, and Spain. In total, 17 and 34 patients were below 18 years old and were adults respectively. The most commonly reported dose was 10 mg/kg, which was received by 25 (73.5%) patients. According to reports, 58.8% of patients completed the questionnaire. Twelve (35%) patients did not require a repeat surgery. The time interval between surgical procedures has increased for patients who require them. Conclusion: SB may be a promissory treatment and control option for RRP. More research is needed to evaluate the efficiency and adverse effects in various populations.

Introduction: Continuous subcutaneous insulin infusion (CSII) has emerged as a potential solution for diabetes management during the pandemic, as it reduces the need for in-person visits and allows for remote monitoring of patients. Telemedicine has also become increasingly important in the management of diabetes during the pandemic, as it allows healthcare providers to provide remote consultations and support. Here, we discuss the implications of this approach for diabetes management beyond the pandemic, including the potential for increased access to care and improved patient outcomes. Methods: We performed a longitudinal observational study between 1 March 2020 and 31 December 2020 to evaluate glycemic parameters in diabetic patients with CSII in a telehealth service. Glycemic parameters were time in range (TIR), time above range, time below range, mean daily glucose, glucose management indicator (GMI), and glycemic variability control. Results: A total of 36 patients were included in the study, with 29 having type 1 diabetes and 6 having type 2 diabetes. The study found that the proportion of patients achieving target glucose variability and GMI remained unchanged during follow-up. However, in patients with type 2 diabetes, the time in target range increased from 70% to 80%, and the time in hyperglycemia decreased from 2% to 0%. Conclusions: The results of this study suggest that telemedicine is a strategy for maintaining glycemic control in patients using CSII. However, the lack of access to the internet and adequate telemonitoring devices make it difficult to use on a large scale in emerging countries like ours.

Background: Workplace mobbing affects approximately 20% of workers worldwide, yet about 70% of victims do not report it, limiting the full understanding of its true impact. While previous research has established its association with mental health disorders, the broader burden—including burden of disease (BOD), cost of illness (COI), and productivity loss (PL)—remains underexplored. This scoping review aims to address this gap by mapping the existing literature on the BOD and economic costs associated with mobbing-related mental health disorders. Methods: We conducted a scoping review following the Preferred Reporting Items for Systematic Reviews and Meta-Analyses extension for Scoping Reviews (PRISMA-ScR) guidelines. A systematic search in National Library of Medicine's bibliographic database (MEDLINE), Latin American and Caribbean Literature in Health Sciences (LILACS), Embase, Scopus, and PsycInfo databases (until June 30, 2021) identified primary studies and reviews assessing BOD, COI, or PL in adults exposed to workplace mobbing. Articles were screened independently by two reviewers in two phases (title/abstract and full-text review). Data extraction focused on study characteristics and key findings, which were categorized into predefined thematic domains. Results: Fourteen studies published between 2008 and 2020 met the selection criteria (71.4% primary studies, 28.6% reviews). The definition of mobbing varied across studies, and frequently, different terms were used interchangeably. None of the included studies quantified disease burden using standard metrics such as disability-adjusted life years (DALYs). Instead, PL was assessed indirectly through absenteeism, presenteeism, and work performance assessments. Conclusions: Mobbing is a significant occupational health issue with substantial mental health implications, yet research on its economic and disease burden remains limited. The heterogeneity in definitions and methodologies across studies hampers comparability and synthesis. Future research should adopt standardized definitions and employ robust burden-of-disease frameworks, such as DALYs and Quality-Adjusted Life Years (QALYs), to better quantify the impact of mobbing on mental health and work productivity.

Background: Dengue-associated hemophagocytic lymphohistiocytosis (DA-HLH) is a rare but severe hyperinflammatory complication of dengue. Its clinical overlap with severe dengue often delays recognition. We describe the clinical, laboratory and therapeutic characteristics of pediatric patients with DA-HLH in a dengue-endemic region of Latin America. Methods: We conducted a retrospective cohort study of pediatric patients diagnosed with DA-HLH at a tertiary-care center in Cali, Colombia, between 2013 and 2024. HLH was diagnosed using HLH-2004 criteria and supported by the HScore. Clinical features, laboratory parameters, treatment regimens and outcomes were analyzed. Associations between extreme biomarker values (below Q1 or above Q3) and mortality were assessed using Fisher exact test. Results: Nineteen patients were included, with a median age of 7 years. Fever and cytopenias were present in all cases, and hepatomegaly was frequently observed. Hyperferritinemia occurred in nearly all patients. Viral coinfections—most commonly Epstein–Barr virus and cytomegalovirus—were identified in over one-third of cases. Overall mortality was 21.1% and occurred exclusively among patients with significant underlying comorbidities. In this exploratory analysis, elevated total bilirubin was the only laboratory parameter associated with mortality. Conclusions: DA-HLH should be considered in pediatric patients with dengue who present with persistent fever, cytopenias, hepatic dysfunction and marked hyperferritinemia. In this exploratory analysis, elevated bilirubin appeared to reflect severe systemic and hepatic involvement rather than an independent prognostic factor, while viral coinfections may contribute to disease severity. Early recognition and individualized immunomodulatory management are essential, and larger multicenter studies are needed to validate these findings.

Objetivo: Describir las características clínicas de las enfermedades alérgicas (EA) como comorbilidades —distintas de las enfermedades atópicas primarias (EAP)— en pacientes pediátricos con diagnóstico de errores innatos de la inmunidad (IEI). Métodos: Estudio observacional y retrospectivo, efectuado en una población pediátrica con diagnóstico de IEI y comorbilidad alérgica, atendidos entre 2013 y 2023. El diagnóstico se basó en los criterios de ESID y IUIS-2022. Se realizó un análisis descriptivo de variables (frecuencias/porcentajes). Para las variables cualitativas se utilizó razón de momios (OR), con la intención de estimar la probabilidad de sensibilización alérgica. Los análisis se realizaron con R Studio versión 3.2.2. Resultados: Se registraron 366 pacientes con IEI y de estos 238 manifestaron EA concomitante (59.6% hombres; edad media: 5 años). Los tipos de IEI más frecuentes fueron las deficiencias específicas de anticuerpos (84%), seguidas por inmunodeficiencias combinadas asociadas a síndromes (8%), defectos congénitos de fagocitos (2.9%), inmunodeficiencias combinadas (2.5%), enfermedades autoinflamatorias (1.7%) y defectos de inmunidad innata (0.8%). Las EA incluyeron asma (48.7%), rinitis (18.9%), dermatitis atópica (15.1%), alergia alimentaria (8.4%), urticaria aguda (5%) y urticaria crónica (3.8%). Conclusión: Las EA son un signo de alerta cada vez más reconocido para la detección temprana de IEI. Su coexistencia, sin ser necesariamente EAP, destaca la necesidad de un abordaje integral y multidisciplinario. Palabras clave: Errores innatos de la inmunidad; Enfermedades alérgicas; Sensibilización; Reacciones de hipersensibilidad.

Background: The epidemiology, morbidity, and burden of disease related to airway sequelae associated with invasive mechanical ventilation in the context of the COVID-19 pandemic remain unclear. Objective: This scoping review aims to summarize the current knowledge regarding airway sequelae after severe SARS-CoV-2 infection. This knowledge will help guide research endeavors and decision-making in clinical practice. Methods: This scoping review will include participants of all genders, and no particular age group who developed post–COVID-19 airway-related complication will be excluded. No exclusion criteria will be applied from country, language, or document type. The information source will include analytical observational studies. Unpublished data will not be completely covered as gray literature will be covered. A total of 2 independent reviewers will participate in the process of screening, selection, and data extraction, and the whole process will be performed blindly. Conflict between the reviewers will be solved through discussion and an additional reviewer. The results will be reported by using descriptive statistics, and information will be displayed on RedCap (Research Electronic Data Capture). Results: The literature search was conducted in May 2022 in the following databases: PubMed, Embase, SCOPUS, Cochrane Library, as well as LILACS and gray literature to identify observational studies; a total of 738 results were retrieved. The scoping review will be finished by March 2023. Conclusions: This scoping review will describe current knowledge on the most frequently encountered laryngeal or tracheal sequelae in patients exposed to mechanical ventilation due to SARS-CoV-2 infection. This scoping review will find the incidence of airway sequelae post COVID-19 and the most common sequelae such as airway granuloma, vocal fold paralysis, and airway stenoses. Future studies should evaluate the incidence of these disorders. International Registered Report Identifier (IRRID): DERR1-10.2196/41811